RxDoctor Payments Data

Christa Blane

Family · Dover, TNNPI 1851327977

Payments from drug & device makers

$1,479in general payments, 2019–2025

Across 85 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$472
  • Lilly USA, LLC$231
  • AbbVie$137
  • AstraZeneca$109
  • Medtronic$97
  • Amgen$91
  • plus $341 from 11 others

What the payments were for

  • Food & beverage$1,479100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,479 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$75,931
Medicare patients
291
Services billed
1,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide158$207,134
MounjaroTirzepatide82$107,752
FarxigaDapagliflozin Propanediol137$101,172
EliquisApixaban73$59,916
Tresiba Flextouch U-200Insulin Degludec45$43,852
TrulicityDulaglutide16$29,866
Repatha SureclickEvolocumab39$21,340
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$20,707
XareltoRivaroxaban21$20,250
JardianceEmpagliflozin28$19,528
JanumetSitagliptin Phos/Metformin Hcl19$18,983
JanuviaSitagliptin Phosphate24$15,169
LinzessLinaclotide18$12,456
Repatha SyringeEvolocumab27$11,342
MyrbetriqMirabegron16$8,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$472$207,134158 claims
Lilly USA, LLCMounjaro, Trulicity$231$137,61898 claims
AstraZenecaFarxiga, Nexium$109$104,599150 claims
MerckJanumet, Januvia$41$34,15343 claims
Boehringer IngelheimJardiance$15$19,52828 claims
AbbVieLinzess, Synthroid$137$15,26285 claims
Astellas Pharma US IncMyrbetriq$18$8,05716 claims
Esperion Therapeutics, Inc.Nexletol$77$4,60412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.

Other family in Dover

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →